Investors Are Watching: Canadian Solar Inc. (NASDAQ:CSIQ), Vonage Holdings (NYSE:VG), Tableau Software (NYSE:DATA), Seaboard Corp. (NYSEMKT:SEB), Consolidated Edison, Inc. (NYSE:ED)
Shares of Canadian Solar (NASDAQ:CSIQ) have been given a consensus recommendation of “Buy” by the twelve ratings firms that are currently covering the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Canadian Solar Inc. (NASDAQ:CSIQ) belongs to Technology sector. Its net profit margin is 2.10% … Continue reading Investors Are Watching: Canadian Solar Inc. (NASDAQ:CSIQ), Vonage Holdings (NYSE:VG), Tableau Software (NYSE:DATA), Seaboard Corp. (NYSEMKT:SEB), Consolidated Edison, Inc. (NYSE:ED)
Stocks in Focus: API Technologies (NASDAQ:ATNY), Intercept Pharmaceuticals (NASDAQ:ICPT), OvaScience (NASDAQ:OVAS), Charles & Colvard Ltd. (NASDAQ:CTHR)
API Technologies Corp. (NASDAQ:ATNY), a leading provider of high performance RF/microwave, power, and security solutions for critical and high-reliability applications, announced today the launch of configurable frequency synthesizers (Models LCFS-X), the newest addition to the Company’s line of standard RF / microwave products. API Technologies Corp. (NASDAQ:ATNY) belongs to Technology sector. Its net profit margin is -7.90% and weekly performance is 0.00%. On last trading … Continue reading Stocks in Focus: API Technologies (NASDAQ:ATNY), Intercept Pharmaceuticals (NASDAQ:ICPT), OvaScience (NASDAQ:OVAS), Charles & Colvard Ltd. (NASDAQ:CTHR)
Today’s Watch List: bluebird bio (NASDAQ:BLUE), ReneSola (NYSE:SOL), Primo Water (NASDAQ:PRMW), Weight Watchers International, Inc. (NYSE:WTW), Jumei International (NYSE:JMEI)
On Aug. 12, 2014 bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014. bluebird bio, Inc. (NASDAQ:BLUE) belongs to Healthcare sector. Its weekly performance is -1.27%. On last trading day company shares ended up $33.55. bluebird bio, Inc. (NASDAQ:BLUE) … Continue reading Today’s Watch List: bluebird bio (NASDAQ:BLUE), ReneSola (NYSE:SOL), Primo Water (NASDAQ:PRMW), Weight Watchers International, Inc. (NYSE:WTW), Jumei International (NYSE:JMEI)
Stocks in News: SunEdison (NYSE:SUNE), UniFirst Corp. (NYSE:UNF), Symetra Financial Corporation (NYSE:SYA), Income Opportunity Realty Investors Inc. (NYSEMKT:IOT)
Research analysts at Goldman Sachs started coverage on shares of Sunedison (NASDAQ:SUNE) in a report released on Tuesday. The firm set a “buy” rating on the stock. SunEdison, Inc. (NYSE:SUNE) shares decreased -3.83% in last trading session and ended the day at $20.82. SUNE Gross Margin is 6.80% and its return on assets is -18.60%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is 14.90%. UniFirst Corp. (NYSE:UNF) Director Michael Iandoli … Continue reading Stocks in News: SunEdison (NYSE:SUNE), UniFirst Corp. (NYSE:UNF), Symetra Financial Corporation (NYSE:SYA), Income Opportunity Realty Investors Inc. (NYSEMKT:IOT)
Discover’s Momentum Continues in 1Q
Discover Financial Service DFS reported net income of $673 million, or $1.33 per diluted share, for the first quarter of 2013. The narrow-moat company continued to generate strong momentum across business lines, increasing book value more than 5% during the quarter, and we may moderately increase our fair value estimate as we incorporate the quarter’s results and transfer coverage to a new analyst. In contrast … Continue reading Discover’s Momentum Continues in 1Q
Biotech Stock in Focus: Bayer Continues Progress with Eylea
Bayer’s (BAYRY) has progressed well with its newly launched products in the last few quarters. Drugs like Eylea (Eye), Stivarga (oncology), Xarelto (anticoagulant), Xofigo (oncology) and Adempas (pulmonary hypertension) posted sales of €598 million in the first quarter and are expected to contribute around €2.8 billion in 2014. The company is looking to get these products approved for additional indications as well. Last week, Bayer … Continue reading Biotech Stock in Focus: Bayer Continues Progress with Eylea
